Regulatory

BMS secures FDA acceptance for Camzyos sNDA

Pharmaceutical Business Review

The regulator granted the application priority review for this indication, assigning a Prescription Drug User Fee Act (PDUFA) date of 30 September 2026.

Cardiovascular

Read full story

pharminent June 2, 2026 (Last updated: June 4, 2026)

Pharmaceutical Business Review

The regulator granted the application priority review for this indication, assigning a Prescription Drug User Fee Act (PDUFA) date of 30 September 2026.

Cardiovascular

Read full story

Related Stories

Replimune gets early August decision date for twice-rejected melanoma drug

Ionis secures market expansion for Tryngolza as FDA clears severe hypertriglyceridemia use

MSD’s Keytruda-Padcev combo secures EC approval for MIBC

You May Have Missed

Lilly Medicare GLP-1 Bridge Launches July 1 With Foundayo and Zepbound

Moderna Maps R&D ‘Horizons’ as 2028 Break-Even Goal Looms

Replimune gets early August decision date for twice-rejected melanoma drug

Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms